NCT00122629View on ClinicalTrials.gov

Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders

PHASE3TerminatedINTERVENTIONAL
Enrollment

405

Participants

Timeline

Start Date

October 31, 2000

Study Completion Date

May 31, 2003

Conditions
Hepatitis C, Chronic
Interventions
DRUG

peg-interferon alfa-2b

DRUG

ribavirin

DRUG

amantadine

Trial Locations (1)

69288

Service d'Hépato-Gastroentérologie Hopital Hotel Dieu, Lyon

Sponsors

Collaborators (1)

Schering-Plough
All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV